Personalised mRNA vaccine reduces risk of melanoma returning
A phase 3 study shows better outcomes, but the vaccine has not yet been approved.
A personalised mRNA vaccine reduced the risk of a high-risk melanoma returning or death by 42 per cent in a large phase 3 study. The treatment was combined after surgery with pembrolizumab, an existing form of immunotherapy.
The results of the INTerpath-001 study were reportedly presented this week at the congress of the European Society for Medical Oncology in Madrid and published as a so-called ahead-of-print publication in Cancer Discovery. The study involved 1,137 people whose high-risk melanoma had been surgically removed.
Participants in the combination group received pembrolizumab together with the personalised vaccine intismeran autogene. The control group received pembrolizumab alone. After two years, 82 per cent of participants in the combination-therapy group were free of disease recurrence, compared with 70 per cent in the control group.
The vaccine is made separately for each patient. To do this, researchers analyse tumour tissue and select so-called neoantigens: abnormal proteins characteristic of the tumour. The mRNA is intended to teach the immune system to recognise these characteristics, enabling it to attack cancer cells more precisely.
The reported 42 per cent reduction in risk is a relative measure. The proportion of participants who were free of recurrence after two years was 12 percentage points higher in the combination group. The researchers also reported a 38 per cent reduction in the risk of distant metastases.
According to independent cancer researchers, the results are an important step for personalised cancer treatment. At the same time, the treatment involves a combination with pembrolizumab and patients with a specific type and stage of melanoma. The results therefore do not automatically say anything about other types of cancer or about people who have not undergone surgery.
The vaccine is not yet a standard treatment and has not yet been approved as a standalone medicine. Whether and when the vaccine will become available as a standard treatment has not yet been established.
Also show where in Europe and in the world
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The main study results, numbers and risk figures are confirmed by the publication data and independent medical reporting. The article makes clear that these are research findings and that approval and use have not yet been established.
- confirmed The phase 3 study included 1,137 patients with high-risk melanoma. — Confirmed in the PubMed summary and The ASCO Post. source
- confirmed The vaccine reduced the risk of recurrence or death by 42 per cent. — Reported in the study publication and by AP. source
- confirmed After two years, 82 per cent compared with 70 per cent were free of recurrence. — Reported by AP and additional medical reporting. source
- confirmed The vaccine has not yet been approved as a standard treatment. — The sources describe research results; no marketing authorisation is reported. source
Editor's note
The phase 3 results were recently presented and registered as an ahead-of-print publication. The relative reduction in risk was checked against the absolute figures; approval and broad applicability remain uncertain.Sources
More on this in Dutch media
- De Telegraaf — „melanoom mrna”
- AD — „melanoom mrna”
- de Volkskrant — „melanoom mrna”